adaptimmune
reports
financial
results
business
update
data
phase
trial
liver
cancer
presented
ilc
confirm
safety
profile
demonstrate
potential
benefit
patients
safety
response
data
dose
escalation
cohorts
surpass
trial
presented
sitc
durability
response
data
patients
synovial
sarcoma
phase
trial
presented
ctos
virtual
investor
day
planned
november
financial
guidance
confirmed
funded
conference
call
held
today
est
gmt
philadelphia
oxfordshire
united
kingdom
globe
newswire
adaptimmune
therapeutics
plc
nasdaq
adap
leader
cell
therapy
treat
cancer
today
reported
financial
results
provided
business
update
third
quarter
ended
september
later
month
present
data
sitc
ctos
data
presented
sitc
dose
escalation
cohorts
surpass
trial
confirm
highly
active
agent
across
range
tumors
ctos
present
data
regarding
durability
responses
synovial
sarcoma
support
ambition
market
finally
investor
day
lay
broader
strategy
including
opportunity
see
pipeline
said
adrian
rawcliffe
adaptimmune
chief
executive
officer
recruitment
clinical
trials
steadily
recovering
following
first
wave
projected
patient
numbers
currently
look
good
remainder
year
planned
milestones
four
posters
presented
virtual
sitc
meeting
november
poster
entitled
initial
safety
efficacy
product
attributes
surpass
trial
spear
therapy
incorporating
affinity
optimized
tcr
targeting
update
dose
escalation
cohorts
patients
total
poster
entitled
inhibition
akt
signaling
expansion
patient
leukocyte
material
generates
spear
enhanced
functional
potential
vitro
data
indicating
akt
inhibition
manufacture
spear
results
consistent
expansion
phenotype
final
product
two
posters
previously
terminated
phase
program
one
lung
cancer
trial
one
triple
tumor
trial
melanoma
urothelial
head
neck
cancers
durability
response
data
patients
synovial
sarcoma
phase
trial
presented
oral
presentation
virtual
ctos
conference
immunotherapy
sarcoma
session
november
est
investor
day
held
november
clinical
updates
management
clinical
sites
continues
evolve
increase
recruitment
enrollment
latter
part
ongoing
clinical
trials
recruiting
well
remains
target
complete
enrollment
first
half
track
start
phase
trial
gastroesophageal
cancers
gastric
esophageal
esophagogastric
junction
first
half
data
update
phase
trial
presented
oral
presentation
poster
international
liver
congress
confirmed
safety
profile
demonstrated
potential
benefit
patients
hepatocellular
carcinoma
four
patients
treated
billion
transduced
cells
best
responses
one
complete
response
one
patient
stable
disease
two
patients
progressive
disease
presented
poster
esmo
summarizing
design
first
combination
clinical
trial
pembrolizumab
financial
results
three
nine
month
periods
ended
september
cash
liquidity
position
september
adaptimmune
cash
cash
equivalents
million
total
liquidity
million
september
adaptimmune
cash
cash
equivalents
million
total
liquidity
million
revenue
revenue
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
revenue
increased
due
commencement
development
activity
astellas
collaboration
agreement
increased
development
activity
gsk
collaboration
license
agreement
revenue
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
revenue
increased
due
commencement
development
activity
astellas
collaboration
agreement
increased
development
activity
gsk
collaboration
license
agreement
research
development
r
expenses
r
expenses
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
r
expenses
higher
three
nine
months
ended
september
due
recognition
accrued
purchase
commitment
expenses
related
supply
technology
million
research
development
result
entering
collaboration
agreement
biotech
august
period
ended
september
also
included
million
research
development
result
entering
collaboration
agreement
alpine
immune
sciences
may
r
expenses
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
r
expenses
higher
three
nine
months
ended
september
due
recognition
accrued
purchase
commitment
expenses
related
supply
technology
million
research
development
result
entering
collaboration
agreement
biotech
august
period
ended
september
also
included
million
research
development
result
entering
collaboration
agreement
alpine
immune
sciences
may
general
administrative
g
expenses
g
expenses
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
increase
three
months
ended
september
primarily
driven
increase
professional
fees
investment
systems
costs
associated
buildout
commercial
capabilities
g
expenses
three
nine
months
ended
september
million
million
respectively
compared
million
million
periods
increase
three
months
ended
september
primarily
driven
increase
professional
fees
investment
systems
costs
associated
buildout
commercial
capabilities
net
loss
net
loss
attributable
holders
company
ordinary
shares
three
nine
months
ended
september
million
million
respectively
per
ordinary
share
respectively
compared
million
million
per
ordinary
share
periods
financial
guidance
company
believes
existing
cash
cash
equivalents
marketable
securities
fund
company
current
operations
detailed
company
quarterly
report
form
fiscal
quarter
ended
september
filed
securities
exchange
commission
following
earnings
release
conference
call
webcast
information
company
host
live
teleconference
est
gmt
today
november
live
webcast
conference
call
available
investor
section
adaptimmune
corporate
website
archive
available
call
address
participate
live
conference
call
please
dial
canada
international
placing
call
please
ask
joined
adaptimmune
conference
call
provide
confirmation
code
adaptimmune
adaptimmune
biopharmaceutical
company
focused
development
novel
cancer
immunotherapy
products
people
cancer
company
unique
specific
peptide
enhanced
affinity
receptor
platform
enables
engineering
target
destroy
cancer
across
multiple
solid
tumors
statements
release
contains
statements
within
meaning
private
securities
litigation
reform
act
pslra
statements
involve
certain
risks
uncertainties
risks
uncertainties
could
cause
actual
results
differ
materially
indicated
statements
include
without
limitation
success
cost
timing
product
development
activities
clinical
trials
ability
successfully
advance
tcr
therapeutic
candidates
regulatory
commercialization
processes
description
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
statements
well
risks
relating
business
general
refer
quarterly
report
form
filed
sec
august
sec
filings
statements
contained
press
release
speak
date
statements
made
undertake
obligation
update
statements
reflect
subsequent
events
circumstances
total
liquidity
financial
measure
total
liquidity
financial
measure
total
cash
cash
equivalents
marketable
securities
components
appears
separately
condensed
consolidated
balance
sheet
gaap
financial
measure
directly
comparable
total
liquidity
cash
cash
equivalents
reported
condensed
consolidated
financial
statements
reconciles
total
liquidity
follows
millions
september
december
cash
cash
equivalents
marketable
securities
debt
securities
total
liquidity
company
believes
presentation
total
liquidity
provides
useful
information
investors
management
reviews
total
liquidity
part
management
overall
liquidity
financial
flexibility
capital
structure
leverage
condensed
consolidated
statement
operations
unaudited
thousands
except
per
share
data
three
months
ended
nine
months
ended
september
september
revenue
operating
expenses
research
development
including
losses
accrued
firm
purchase
commitments
general
administrative
total
operating
expenses
operating
loss
interest
income
expense
income
net
loss
income
taxes
income
taxes
net
loss
attributable
ordinary
shareholders
net
loss
per
ordinary
share
basic
diluted
weighted
average
shares
outstanding
basic
diluted
condensed
consolidated
balance
sheets
unaudited
thousands
except
share
data
september
december
assets
current
assets
cash
cash
equivalents
marketable
securities
debt
securities
current
assets
prepaid
expenses
including
current
portion
clinical
materials
total
current
assets
restricted
cash
clinical
materials
operating
lease
assets
net
accumulated
amortization
property
plant
equipment
net
accumulated
depreciation
intangibles
net
accumulated
amortization
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
operating
lease
liabilities
current
accrued
expenses
accrued
liabilities
deferred
revenue
current
total
current
liabilities
operating
lease
liabilities
deferred
revenue
liabilities
total
liabilities
stockholders
equity
common
stock
ordinary
shares
par
value
authorized
issued
outstanding
authorized
issued
outstanding
additional
paid
capital
accumulated
comprehensive
loss
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
condensed
consolidated
cash
flow
statement
unaudited
thousands
nine
months
ended
september
cash
flows
operating
activities
net
loss
adjustments
reconcile
net
loss
net
cash
used
operating
activities
depreciation
amortization
compensation
expense
unrealized
foreign
exchange
gains
losses
changes
operating
assets
liabilities
decrease
increase
receivables
operating
assets
decrease
operating
assets
decrease
increase
payables
current
liabilities
increase
deferred
revenue
net
cash
used
operating
activities
cash
flows
investing
activities
acquisition
property
plant
equipment
acquisition
intangibles
maturity
redemption
marketable
securities
investment
marketable
securities
net
cash
used
provided
investing
activities
cash
flows
financing
activities
proceeds
issuance
common
stock
net
issuance
costs
proceeds
exercise
stock
options
net
cash
provided
financing
activities
effect
currency
exchange
rate
changes
cash
cash
equivalents
restricted
cash
net
increase
decrease
cash
cash
equivalents
restricted
cash
cash
cash
equivalents
restricted
cash
start
period
cash
cash
equivalents
restricted
cash
end
period
adaptimmune
contacts
media
relations
sébastien
desprez
vp
communications
investor
relations
investor
relations
juli
miller
senior
director
investor
relations
total
liquidity
financial
measure
explained
reconciled
directly
comparable
financial
measures
prepared
accordance
gaap
